236 records found.
Nov 08, 2019
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Nov 08, 2019
BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA®
Nov 07, 2019
FlexEnable Acquires Merck's OTFT Materials Portfolio for Flexible Displays
Nov 06, 2019
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
Nov 06, 2019
4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA®
Nov 05, 2019
Global Laboratory Filtration Market 2019: Top Players are Cantel Medical, Sigma-Aldrich, 3M, GE Healthcare, Pall, Merck Millipore, Sartorius, Thermo Fisher Scientific And Macherey-Nagel
Oct 28, 2019
Applied BioMath, LLC Announces Participation at The Society for Immunotherapy of Cancer (SITC)
Oct 24, 2019
Merck Manuals Unveils Answers to Parents' Most Common Eczema Questions
Oct 23, 2019
Genedata and Merck Co-Develop A Digital Platform For Translational and Clinical Biomarker Research
Oct 22, 2019
Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma
Oct 20, 2019
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
Oct 08, 2019
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Sep 27, 2019
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress
Sep 23, 2019
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types
Sep 23, 2019
New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care
Sep 17, 2019
FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma
Sep 12, 2019
Menarini: Elcin Barker Ergun Group CEO
Sep 11, 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Sep 10, 2019
EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
Sep 04, 2019
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations

Pages